Other languages SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Real-time Estimate Cboe BZX Other stock markets 01:08:36 2024-05-03 pm EDT			5-day change	1st Jan Change
1.72 ^USD	-3.37%		+12.33%	-22.43%

Apr. 09	SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	CI
Mar. 28	SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	Apr. 09
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference	Jan. 29
SCYNEXIS Amends License Agreement With GlaxoSmithKline Intellectual Property; Shares Drop Premarket	Jan. 03
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology	23-10-24
SCYNEXIS Recalls Two Lots of Brexafemme Due to Potential for Cross Contamination with Non-Antibacterial Drug Substance	23-09-28
SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance	23-09-27
Sector Update: Health Care Stocks Advancing Late Afternoon	23-09-25
Top MIdday Decliners	23-09-25
SCYNEXIS Recalls Brexafemme on Cross Contamination Risk; Shares Fall	23-09-25
SCYNEXIS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
SCYNEXIS Says New Drug Application for Vulvovaginal Candidiasis Treatment Accepted for Review in China	23-07-20
Scynexis Says $25 Million Performance-Based Development Milestone Achieved as Part of GSK License Deal	23-06-21
Scynexis Closes Exclusive Brexafemme License Deal With GSK	23-05-12
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Top Midday Gainers	23-03-30
GSK : conclut un accord de licence exclusif avec Scynexis	23-03-30
GSK sees $500 million peak sales for yeast infection pill licensed from Scynexis	23-03-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Other languages

Filters